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Determination of HPV status has become clinically relevant for patient stratification under 
UICC TNM8 staging. Within the UK, a combination of p16 IHC and HPV DNA-ISH is 
recommended for classifying HPV status. This study will assess a series of clinically 
applicable second-line molecular tests to run in combination with p16 IHC to optimally 
determine HPV status. 
 
Methods 
The ability of HPV RNA-ISH, HPV DNA-ISH and HPV DNA-PCR to identify p16-
positive/HPV-positive patients was investigated in a population-based OPSCC cohort of 
patients diagnosed in Northern Ireland from 2000-2011.  
 
Results 
Only 41% of the Northern Irish OPSCC patient population was associated with HPV-driven 
carcinogenesis. Both ISH assays were more specific than the DNA-PCR assay (100% and 
95% vs 67%) and were less likely to be affected by pre-analytical factors such as increasing 
block age. A pooled HPV genotype probe for RNA-ISH was found to be the most accurate 
molecular assay assessed (95% accuracy) when compared to p16 positivity. 
 
Conclusions 
Our study demonstrates the advantage of tissue-based molecular assays when determining 
HPV status in retrospective samples. Specifically, we demonstrate the enhanced sensitivity 
and specificity of ISH techniques compared to PCR based methodology when working with 




As p16 IHC is a relatively inexpensive, accessible and sensitive test for stratifying patients by 
HPV status, this study finds more patients would benefit from first-line p16 IHC followed by 








Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinomas (OPSCC) are 
distinct to HPV-negative OPSCC.
1
 Patients presenting with HPV-related OPSCC tend to be 
younger, non-smokers, non-drinkers and to have fewer co-morbidities compared to their 
HPV-negative counterparts.
2
 Clinical trials comparing HPV-related and HPV-negative 
OPSCC have conclusively demonstrated that patients with HPV-related OPSCC have better 
prognosis.
3
 Subsequently, molecular stratification of patients with OPSCC based on HPV 
status has been considered for the clinical management of OPSCC following early results 
from clinical trials.
4
 Most recently, the eighth edition of the American Joint Committee on 
Cancer and the Union for International Cancer Control TNM staging guidelines have adjusted 
the staging criteria for HPV-related OPSCC, down-staging them.
5,6
 Underpinning the new 
staging criteria and  the advances in the clinical management of OPSCC is how HPV status is 
determined. The most recent guidelines produced by the College of American Pathologists 
detail that p16 IHC testing alone is sufficient for the molecular stratification of OPSCC.
1
 
However, in the UK, the Royal College of Pathologists still promote use of HPV DNA-ISH 




The aim of this study was to compare different types of molecular HPV tests against p16 IHC 
as a second line-test in a large, population-based UK cohort of OPSCC patients. Three HPV 
tests suitable for clinical HPV testing on FFPE were compared to p16 IHC as a single test and 
as a second-line test, with their effect on patient outcome evaluated by survival analyses and 
relationship to p16 positivity. This study will address which molecular assay is optimal for 







Materials and Methods 
Patients 
The study was conducted according to the Good Clinical Practice guidelines and the 
Declaration of Helsinki. OPSCCs diagnosed in Northern Ireland from 2000 to 2011 were 
identified within the Belfast Health and Social Care Trust under ethical approval from the 
Northern Ireland Biobank (OREC 16/NI/0030; NIB 11/0001). Patients identified in this study 
were considered representative of all OPSCC patients in Northern Ireland during the study 
period. Inclusion criteria were based on confirmed diagnosis of an untreated primary OPSCC; 
here defined as either base of tongue (C01), soft palate (C05.1), uvula (C05.2) tonsils (C09), 
or oropharynx not otherwise specified (C10.9).  
 
Clinical data were retrieved from individual patient electronic clinical records through the 
Northern Ireland Cancer Registry. Data recorded for each cohort included sex, age, TNM7 
stage, treatment received, smoking history, alcohol history, date of diagnosis and death. 
Overall survival was defined as the time from diagnosis until time of death as recorded on the 




Using patient FFPE material arrayed on tissue microarrays (TMAs) all patients were assessed 
for p16 IHC as previously described using a Ventana Benchmark Autostainer with a 
commercial kit (CINtec® p16 Histology; Roche, Tuscon AZ, USA; catalog number: 725-
4713) at the Newcastle upon Tyne Hospitals NHS Foundation Trust.
9
 For each patient, 
triplicate TMA cores were independently assessed by two investigators for all assays. 




least 70% of tumor cells.
10
 Digital image analysis using QuPath was applied to confirm 




HPV RNA-ISH was carried out on all TMAs and scored only for cores for which suitable 
mRNA integrity had been detected with positive (PPIB) and negative (DapB) reagent 
controls (Advanced Cell Diagnostics; Newark, CA, USA; catalog numbers: 313901 for PPIB 
and 310043 for DapB).
12
 Patient FFPE material positive by PPIB but negative for DapB were 
considered suitable for analysis by the test probe for HPV. High-risk HPV RNA-ISH was 
undertaken using RNAscope 2.0 manual assay with a pooled HPV genotype detection kit 
(Probe-HPV-HR18 recognising HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 
68, 73, and 82 E6/E7 mRNA, Advanced Cell Diagnostics, catalog number: 312591) within 
the Northern Ireland Molecular Pathology Laboratory. Patients were considered HPV RNA-
ISH positive if the tumor tissue demonstrated punctate dots of brown reaction product 




High-risk HPV DNA-ISH was conducted on TMAs as previously described using a Ventana 
Benchmark Autostainer with a commercial kit (Inform HPV III family 16 probe (B) 
recognising HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 66 subtypes, Roche, catalog 
number: 800-4295) at the Newcastle upon Tyne Hospitals NHS Foundation Trust.
9
 Patients 
were considered positive for HPV DNA-ISH if tumor tissue demonstrated blue reaction 




HPV DNA-PCR was undertaken as previously described using a commercially available 
qualitative PCR-based assay specialised for generalised HPV genotyping (Optiplex HPV 




56, 58, 59, 66, 68, 70, 73 and 82 types, DiaMex; Heidelberg, Germany; catalog number: 
IN0601) at the Scottish HPV Reference Laboratory.
15
 HPV-positive Caski cells and water 
acted as positive and negative controls respectively for the test and were run in parallel. Cross 
contamination, resulting from sectioning was checked on sections taken from a virgin wax 
FFPE block containing no sample. Reagent blanks from the DNA extraction process were 
also checked for cross contamination. For patient genotyping, each sample underwent PCR 
amplification using primers designed for independent, co-amplification of 24 high-risk HPV 
genotypes and the human β globin gene which acted as an internal control for sample 
adequacy. Patients were considered HPV-positive if they were genotyped for a specific HPV 
type and if there was adequate human β globin gene expression. Patients with negative 




Cohort baseline characteristics were compared between patients for known/unknown HPV 
status and p16 status using Pearson’s chi-square test for independence. The gold standard for 
HPV testing in other cancers types uses a PCR-based test on fresh frozen tissue in order to 
determine HPV status of the patient.
16
 The Royal College of Pathologists and the College of 
American Pathologists recognise a lack of fresh frozen material collected in OPSCC for HPV 
testing and have produced guidelines for what should be done to determine HPV status in 
patients with OPSCC. Both recommend use of p16 immunohistochemistry (IHC), a highly 
sensitive if somewhat non-specific biomarker, to identify patients that may have HPV-related 
OPSCC.
1,7,8
 Therefore, determination of sensitivity and specificity of HPV DNA-ISH, HPV 
RNA-ISH and HPV DNA-PCR was carried out against p16-positive patients which is likely 
to become the clinical gold standard for these patients.
17




using logistic regression of p16-negative/HPV-positive and p16-positive/HPV-negative 
patients against incidence before and after 2006. The Welch two sample t test was used to 
determine difference in p16 expression against p16/HPV status.  
 
Overall five-year survival analysis using the Kaplan-Meier method was conducted. Survival 
curves were compared using the log-rank test. The missing indicator method was used to 
handle missing clinical data. Cox proportional-hazards models were used to calculate hazard 
ratios (HR) and associated 95% confidence intervals (CI). Multivariable models were 
developed by backwards selection of age, sex, smoking status, alcohol history, treatment, 
block age and TNM7 staging. 
 
The reporting standards of the study fulfil recommendations set by the STROBE statement 





Clinical Cohort  
From 2000 to 2011, 337 patients with OPSCC were identified in Northern Ireland, Figure 1. 
Following case note review, 43 patients were excluded leaving 294 (100%) patients in the 
overall cohort. Of these, 250 (85%) patients had biopsy or resection specimens’ available for 
HPV testing. HPV status was determined by p16 IHC, HPV genotyping, high-risk HPV 
DNA-ISH and RNA-ISH in 221 (75%) patients. The 221 OPSCC cases analysed in this study 
are considered to be representative of all OPSCC patient’s in Northern Ireland in terms of 





Of the 221 patients assessed in this study, 90 (41%) were p16-positive. Mean follow-up time 
was 3.2 years (Range 0.02-10.00 years). p16-positive OPSCC was more common in patients 
under 60 years of age, those who were non-smokers, those presenting with advanced stage 
according to TNM7 and to have received primary surgery with curative intent (p < 0.0048), 
Table 2.  
 
Comparison of HPV molecular testing to p16 IHC 
HPV DNA-ISH identified the least number of HPV-positive cases (n=67), whilst HPV DNA 
genotyping identified the most (n=114). All cases considered positive by either HPV DNA-
ISH or HPV RNA-ISH were found to be HPV-positive by p16 IHC. Moreover, all cases 
positive by HPV DNA-ISH, were also positive by HPV RNA-ISH resulting in a distinctive 
staining pattern amongst the three tests for each patient, Figure 2. Of all of the p16-positive 
cases, only ten were negative by both ISH techniques. If HPV DNA-ISH had been used alone 
more than double the number of p16-positive/HPV-negative patients (n=23) would have been 
identified. In contrast, a significant proportion of HPV DNA genotyping positive patients 
were not HPV-positive by p16 IHC, DNA-ISH or RNA-ISH (38%). Of interest, HPV DNA 
genotyping was the only molecular HPV assay to identify p16-negative/HPV-positive cases, 
Figure 3A. Using digital image analysis no significant difference was observed for p16 IHC 
expression between patients who were p16-positive/HPV-negative or p16-positive/HPV-
positive (p = 0.1002 and p = 0.0672 for HPV RNA-ISH and HPV DNA-PCR respectively), 
Supplementary Figure S1A and S1B. However, patients who were HPV-positive by HPV 
DNA-PCR and who were classified as p16-negative based on p16 IHC expression (i.e. have 
less than 70% positive staining present in tumour epithelium) were more likely to 
demonstrate even lower levels of p16 IHC expression than patients who were p16-





p16 IHC is a highly sensitive surrogate biomarker used to predict HPV-status in FFPE tissue, 
therefore, the ability of the three molecular assays for appropriate HPV detection was carried 
out against p16 status. All three tests demonstrated comparable sensitivity for the detection of 
HPV in p16-positive cases (89%, 95% CI: 81-95%, for HPV RNA-ISH; 79%, 95% CI: 69-
87%, for HPV DNA-PCR and 74%, 95% CI: 64-83%, for HPV DNA-ISH), Figure 3B. 
Specificity for both ISH techniques was superior to PCR-based HPV detection (100%, 95% 
CI: 87-100%, for HPV RNA- and DNA-ISH vs 67%, 95% CI: 58-75% for HPV DNA-PCR), 
Figure 3C. Out of the three tests, the most accurate was HPV RNA-ISH with the ability to 
detect HPV RNA in 95% (95% CI: 92-98%) of p16-positive cases, followed by HPV DNA-
ISH with 90% (95% CI: 85-93%) and HPV DNA-PCR with 72% (95% CI: 66-78%) 
detection. 
 
Within the Northern Ireland cohort incidence of p16-negative/HPV-positive OPSCC was 
limited to a singular molecular assay; HPV DNA-PCR. Incidence of these p16-
negative/HPV-positive cases was found to decrease with decreasing age of the block in 
patient samples taken before 2006 (p = 0.1530), Figure 3D. In contrast, p16-positive/HPV-
negative cases were seen with similar incidence in all three molecular assays independent of 
FFPE block year (p = 0.0131), Figure 3E.  
 
Prevalence of the HPV-16 Genotype vs other Genotypes driving HPV-related OPSCC 
HPV DNA-PCR determined that HPV-positive patients in the cohort arose from only HPV-
16 (n=110), HPV-18 (n=1) and HPV-33 (n=3; 2 of which co-expressed HPV-16 DNA) 
genotypes, with 98% of HPV DNA genotyping positive cases containing HPV-16 DNA. Of 




PCR, HPV status using high-risk HPV RNA-ISH was assessed independently using a single 
probe targeting HPV-16 only and also a high-risk cocktail probe targeting 18 genotypes. Of 
the HPV-positive cases assessed by HPV RNA-ISH (single probe only), 93% contained 
HPV-16 RNA which concurs with HPV DNA genotyping. Results from both HPV RNA-ISH 
probe sets were concordant except in six cases were the single probe was negative and the 
cocktail probe positive. Of these, according to HPV DNA-PCR, all p16-positive, non-HPV-
16 DNA cases were identified (n=3). The other three cases, which contained HPV-16 DNA 
according to genotyping, were positive by the cocktail probe alone.  
 
Stratification of patient prognosis by HPV molecular testing vs p16 IHC 
Determining ‘HPV’ status was found to have comparable survival for p16 IHC (HR 0.31 
[95% CI: 0.20-0.48]), HPV RNA-ISH (HR 0.26 [95% CI: 0.16-0.42]) and HPV DNA ISH 
(HR 0.23 [95% CI: 0.13-0.40]), but not HPV DNA-PCR (HR 0.67 [95% CI: 0.47-0.97]), 
Figure 4A, 4B, 4C, 4D. Comparable hazard ratios were observed following adjustment for 
age, sex, TNM7 stage, smoking, alcohol history, block age and treatment received indicating 
similar survival predictions in the adjusted models, Supplementary Table S1. Results for p16 
IHC (our gold standard) were not found to vary with respect to covariate strata or missing 
clinicopathological data, Supplementary Figure S2 and Supplementary Table S2. 
Combination of p16 IHC positive and HPV DNA-PCR positive patients to determine HPV 
status improved stratification of patients for survival predictions using HPV DNA-PCR (HR 
0.33 [95% CI: 0.21-0.54]), Figure 4E. Combination of results for p16 IHC and HPV RNA-
ISH (the most accurate HPV molecular assay assessed) demonstrated significant five-year 
survival overall and identified a group of patients who were p16-positive/HPV-negative (Log 
Rank p < 0.0001), Figure 4F. Interestingly, the mortality of p16-positive/HPV-negative 




patients (33%) (HR 0.87 [95% CI: 0.40-1.87]) and this relationship is maintained when 
adjusted for clinicopathological covariates, Supplementary Table S1. Patients who were p16-
negative/HPV-positive by HPV DNA-PCR were not found to have significantly different 
survival outcomes to p16-negative/p16-positive patients (HR 1.25 [95% CI: 0.81-1.95]), 
Supplementary Figure S1C.  
 
Discussion 
Due to its sensitivity, low cost, easy implementation and simple interpretation for 
pathologists p16 IHC has dominated over any other test to gauge HPV status in OPSCC.
20
 
The main aim of the present study was to identify an appropriate second-line test for 
confirming HPV status in p16-positive OPSCC.  
 
The results of the present study demonstrate that only 89% of cases positive for p16 were 
found to transcribe high-risk HPV E6 and E7 mRNA within a clinically and pathologically 
well-defined OPSCC cohort. Such findings are similar to those reported by Morbini et al., 
2015 who also found concomitant expression of HPV in 90% of the p16-positive cases 
identified in the study when using the RNAscope® assay.
21
 These findings are also supported 
by Upile et al., 2014 who proposed that p16 overexpression and HPV-mediated 
carcinogenesis within the oropharynx are often analogous and showed in their cohort that 
91% of p16-positive cases were also HPV-positive by their three-tier algorithm which utilised 
p16 IHC, HPV DNA ISH and qPCR.
22
 A limitation of the findings of Upile et al., 2014, 
however, is that their use of qPCR confirmation is limited to the HPV-16 genotype. In our 
study, HPV DNA-PCR was found to be the worst predictor of p16 positivity. This result was 
not unexpected and is in agreement with Perrone et al 2011 who recognised that qualitative 




to distinguish between driver and passenger DNA in the samples.
23
  In contrast, ISH 
approaches are less likely to detect HPV DNA or RNA as a consequence of non-causal HPV 
or deposition arising from long term storage and may explain why temporal changes between 
ISH and p16 IHC were not observed in the current study.
12
 A limitation of this study is the 
possibility of p16-positive/HPV-negative cases arising due to a sampling error from using 
TMAs for assessment. However, our results are in line with the 10-20% widely cited in the 
literature, despite the relatively small cohort size and use of TMA assessment therefore 
demonstrating the lack of p16 specificity for HPV detection in OPSCC.
2,10,14,21,24-28
 
Moreover, we demonstrate that expression of p16 IHC in patients who were p16-
positive/HPV-negative is not significantly different to patients who are p16-positive/HPV-
positive using digital image analysis, a finding supported in other studies who have assessed 




Based on the published literature there is still some confusion whether there is a long-term 
difference with respect to prognosis between cases that are p16-positive/HPV-negative and 
those that are p16-positive/HPV-positive i.e. true HPV mediated OPSCC. There is emerging 
evidence that p16 IHC alone is not sufficient for stratifying patients by HPV status.
17,30
 
Unfortunately, differences regarding how subgroups were defined or selected have made 
interpretations of existing literature difficult; additionally variabilities in assay utilisation and 
a lack of strict site specification within the cohorts have also created confounding results.
31
 
Differences in site can lead to discrepancies in agreement between studies as outside of the 
oropharynx co-expression of HPV and p16 overexpression is uncommon.
10,29
 Furthermore, 
recent studies have seen the introduction of HPV RNA-ISH included to assess HPV 
status.
13,21,28
 These articles recognise the limitations of using currently available tests for 




implementing at multi-test strategy is required to overcome the limitations of the single 
assays.
27
 A strength of the present study is that all the direct comparison HPV detection 
assays analysed (HPV RNA-ISH, HPV DNA-ISH and HPV DNA-PCR) possessed an 
overlapping range of comparable genotypes; both the HPV RNA-ISH and HPV DNA-PCR 
could detect all twelve of the genotypes detected by HPV DNA-ISH. This meant that through 
the design of this investigation appropriate comparisons regarding the sensitivity and 
specificity of each direct HPV detection assay could be made with respect to p16 positivity. 
Moreover, the prevalence of high-risk genotypes in Northern Ireland was also assessed using 
two methods, HPV RNA-ISH and HPV DNA-PCR. HPV-16 was found to be the most 
frequent driver of HPV-mediated carcinogenesis in the population by both tests, a finding 
supported in the literature.
10,32
 In the current investigation, our findings strongly agree with 
both those published by Rietbergen et al., 2013  as this work presented in this study has 
demonstrated that p16 in the absence of HPV does not lead to improved survival for patients 
with OPSCC. This is in contrast to the College of American Pathologists guidelines, which 
state that there is inadequate evidence to support use of a second line test such as DNA-ISH, 
which is known to lack sensitivity.
1
 This study shows that p16-positive/HPV-negative 
patients have a prognosis that is similar to p16-negative individuals and so emphasizes the 




Another key consideration for standardised HPV testing are ongoing clinical trials, which use 
HPV DNA-ISH rather than RNA-ISH as a patient selection criteria. In the present study an 
additional 13 cases were identified as HPV-positive by HPV RNA-ISH. Whilst both HPV 
DNA-ISH and RNA-ISH were found to be comparable in terms of accuracy, this study 
demonstrated a 14.45% increase in the number of cases considered HPV positive by HPV 




difference in the cases identified as positive by both p16 and HPV DNA-ISH or HPV RNA-
ISH.
21
 Based on this study it is possible that phase III clinical trials in OPSCC, which use 
DNA-ISH rather than RNA-ISH may be under recruiting patients who could have benefited 
from reduced treatment.
33
 Knowing which Molecular HPV assay will be applied, if any, is 
critical as the current study demonstrates differences in specificity between the available 
techniques.  
 
In conclusion, p16 IHC was found to be a very sensitive biomarker as a surrogate for ‘HPV 
status’ and in addition was an excellent choice for a first line clinical test due to its low cost, 
ease of interpretation and its capacity to be easily integrated into diagnostic molecular 
pathology laboratories. Of the three direct HPV detection assays, the two tissue-based assays 
HPV DNA-ISH and RNA-ISH were found to be equally accurate with respect to p16 
overexpression. Both tests demonstrate similar clinical utility as a first line test comparable to 
p16 positivity. Both p16 IHC and HPV DNA ISH are already in place within the diagnostic 
setting, use of the RNAscope® assay would have additional cost implications for undertaking 
clinical validation and is not yet approved by accreditation bodies for single use in clinical 
scenarios. However, compared to HPV DNA-ISH, use of HPV RNA-ISH will reduce the 
number of patients incorrectly considered p16-positive/HPV-negative by approximately half. 
Therefore, the use of p16 IHC in combination with a second line ISH test, preferably RNA-
ISH by RNAscope® on the basis of these results, should be considered. RNA-ISH by 
RNAscope is superior because, due to the uniqueness of the probe design, it has a very high 
signal to noise ratio which makes interpretation of positive vs negative cases unequivocal.
12
 
This combination has been demonstrated to be sensitive, specific and easily interpreted. We 
have previously identified that p16-positive/HPV-negative patients as having distinctly 
poorer survival compared to true HPV-positive patients.
17




need for appropriate validation and integration of HPV RNA-ISH techniques such as the 
RNAscope® assay into the algorithm for determining HPV status in FFPE tissues from 
patients with OPSCC. It also shows the importance of identifying p16-positive/HPV-negative 
cases despite their low incidence within the oropharynx. The work presented in this study is 
the first to definitively compare the effectiveness of HPV molecular tests to p16 status in 
order to determine their benefit as second-line clinical tests. 
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Age (years) .. .. 0.6848 
0-59 111 (50%) 34 (47%) .. 
60 + 110 (50%) 39 (53%) .. 
    
Sex .. .. 0.306 
Male 164 (74%) 49 (67%) .. 
Female 57 (26%) 24 (33%) .. 
    
TNM7 .. .. 0.4971 
I 19 (9%) 8 (11%) .. 
II 28 (13%) 14 (19%) .. 
III 35 (16%) 12 (16%) .. 
IV 130 (59%) 35 (48%) .. 
Missing 9 (4%) 4 (5%) .. 
    
Smoker Status .. .. 0.2951 
Never or Previous 76 (34%) 25 (34%) 
 
Current 91 (41%) 24 (33%) .. 
Missing 54 (24%) 24 (33%) .. 
    




No 34 (15%) 13 (18%) .. 
Yes 104 (47%) 33 (45%) .. 
Missing 83 (38%) 27 (37%) .. 
    
Curative Intent with Surgery .. .. 0.6576 
Yes 64 (29%) 25 (34%) .. 
No 33 (15%) 9 (12%) .. 
No Treatment/Palliative 124 (56%) 39 (53%) .. 
    
Dead or Alive at Censor Date .. .. 0.8947 
Yes 105 (48%) 36 (49%) .. 
No 116 (52%) 37 (51%) .. 
 
Table 1:  Comparison of baseline characteristics between included and excluded 
study patients. Data is presented as number of patients (%). Differences in patient 
characteristics between included and excluded study patients were compared using Fisher's 
exact test for categorical variables. 
 
 




Age (years) .. .. 0.0048 
0-59 56 (62%) 55 (42%) .. 
60 + 34 (38%) 76 (58%) .. 
    
Sex .. .. 0.1403 
Male 72 (80%) 92 (70%) .. 
Female 18 (20%) 39 (30%) .. 
    
TNM7 .. .. <0.0001 
I 1 (1%) 18 (14%) .. 
II 6 (7%) 22 (17%) .. 
III 14 (16%) 21 (16%) .. 
IV 69 (77%) 61 (47%) .. 
Missing 0 (0%) 9 (7%) .. 
    
Smoker Status .. .. <0.0001 
Never or Previous 47 (52%) 29 (22%) .. 
Current 22 (24%) 69 (53%) .. 
Missing 21 (23%) 33 (25%) .. 




Alcohol History .. .. 0.8181 
No 13 (14%) 21 (16%) .. 
Yes 41 (46%) 63 (48%) .. 
Missing 36 (40%) 47 (36%) .. 
    
Curative Intent with Surgery .. .. 0.0024 
Yes 60 (67%) 64 (49%) .. 
No 25 (28%) 39 (30%) .. 
No Treatment/Palliative 5 (6%) 28 (21%) .. 
 
Table 2:  Baseline characteristics of study patients, according to p16 status. Data is 
presented as number of patients (%). Differences in patient characteristics according to p16 




Figure 1. STROBE diagram. 
Figure 1 details the selection process used when identifying the untreated primary OPSCC 
patients and samples used in the current study. 
 
Figure 2.  Staining patterns demonstrated in patient samples by p16 IHC, HPV 
RNA and DNA ISH at x40 magnification.   
Figure 2 contains the staining pattern observed in a patient with p16+/HPV RNA ISH+/HPV 
DNA ISH+ staining (A), a patient with p16+/HPV RNA ISH+/HPV DNA ISH- staining (B), 
a patient with p16+/HPV RNA ISH-/HPV DNA ISH- staining (C) and a patient with p16-
/HPV RNA ISH-/HPV DNA ISH- staining (D).    
 




Figure 3 contains a visual representation of HPV-positive cases by each test in relation to p16 
positivity (A). Forest plots of computed sensitivity (B) and specificity (C) by each HPV test 
to p16-positive OPSCC. Time trend analysis of p16-/HPV+ (D) and p16+/HPV- (E) patients 
in relation to block year. Incidence before and after 2006 was assessed using logistic 
regression. Incidence was not assessed for DNA-ISH and RNA-ISH in D as no patients were 
found to be p16-/HPV+ using these two assays. 
 
Figure 4. Kaplan-Meier estimates of five-year overall survival. 
Figure 4 contains the Kaplan-Meier estimates of five-year overall survival for p16 IHC (A), 
HPV RNA-ISH (B), HPV DNA-ISH (C), HPV DNA-PCR (D), combined p16 IHC/HPV 
DNA-PCR (E), and combined p16 IHC/HPV RNA-ISH (F). Global differences in survival 
curves were compared through use of the log-rank test. 
 




